Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases

Hematology

Volumn 18, Issue 4, 2013, Pages 233-236

  Pequeño Luévano, Myrna ^a   Villarreal Martínez, Laura ^a   Jaime Pérez, José Carlos ^a   Gómez de León, Andrés ^a   Cantú Rodríguez, Olga Graciela ^a   González Llano, Oscar ^a   Gómez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura

Indexed keywords

ANTIHISTAMINIC AGENT; COTRIMOXAZOLE; ITRACONAZOLE; LACTATE DEHYDROGENASE; PARACETAMOL; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CASE REPORT; CLINICAL FEATURE; FEMALE; FOLLOW UP; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STEROIDS;

EID: 84880027332     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000073     Document Type: Article

References (18)

1. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927-35.
2. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. N Engl J Med. 1998;339:1578-84.
3. Pier MM, Flora P. TTP and ADAMTS-13. When is testing appropriate? Hematology. 2007;2007:121-6.
4. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-9.
5. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:66-74.
6. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451-61.
7. Froissart A, Buffet M, Veyradier A, Poullin Provot F, Malot S, Shwarzinger M, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with suboptimal response to plasma exchange. Crit Care Med. 2012;40:104-11.
8. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746-53.
9. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-8.
10. Sadler JE. VonWillebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112:11-8.
11. Ojeda-Uribe M, Federici L, Wolf M, Coppo P, Veyradier A. Successful long-term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion. 2010;50:733-5.
12. Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome. Blood Transfus. 2010; 8:203-10.
13. Iioka F, Shimomura D, Ishii T, Maesako Y, Ohgoe K, Nakamura F, et al. Short-and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic pupura: four case reports. Int J Hematol. 2012;96:506-12.
14. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93:930-3.
15. Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera Garza JL, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116:4783-5.
16. Li Z, Mou W, Lu G, Cao J, He X, Pan X, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93:91-8.
17. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119:3691-7.
18. Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura-favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153:515-9.